A Phase 1/2 trial of CTX001 in sickle cell disease

Trial Profile

A Phase 1/2 trial of CTX001 in sickle cell disease

Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs CTX 001 (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Feb 2018 New trial record
    • 31 Jan 2018 According to a Vertex Pharmaceuticals media release, an Investigational New Drug (IND) Application is planned to support initiation of this trial in 2018 in the U.S.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top